Envestnet Asset Management
HUMA icon

Envestnet Asset Management’s Humacyte HUMA Stock Holding History

Envestnet Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,211
Closed -$45.6K – 4550
2025
Q3 		$45.6K Buy
+26,211
New +$51.4K ﹤0.01% 4480
2025
Q2 		– Sell
-11,605
Closed -$19.8K – 4496
2025
Q1 		$19.8K Buy
+11,605
New +$43.6K ﹤0.01% 4327

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Envestnet Asset Management's HUMA Position: Q4 2025 in Review

Envestnet Asset Management sold out of Humacyte (HUMA) in Q4 2025, closing a stake of 26,211 shares — an estimated $45.6K sold.

Envestnet Asset Management first reported a position in HUMA in Q1 2025 and held it in 2 quarters. The position peaked at $45.6K in Q3 2025. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

  • Envestnet Asset Management reported no remaining Humacyte position as of Q4 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 26,211 Humacyte shares in Q4 2025, an estimated $45.6K.
  • Envestnet Asset Management first reported a position in Humacyte in Q1 2025 and held it in 2 quarters.
  • Envestnet Asset Management's Humacyte position peaked at $45.6K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Envestnet Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.